Search
Veru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
Categories: Experimental Unapproved Treatments for COVID-19Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalOn May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Categories: GABA-B Receptor AgonistsHuman interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigationalIt is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.
Categories: Experimental Unapproved Treatments for COVID-19Ibudilast
go.drugbank.com/drugs/DB05266Investigational(codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume
Categories: Drugs for Obstructive Airway DiseasesSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. … [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAllogeneic Cardiosphere-Derived Cells
go.drugbank.com/drugs/DB15744InvestigationalThey exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication.
DDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia
Deslanoside
go.drugbank.com/drugs/DB01078ApprovedDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnIt also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. … Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules
Categories: Glycoprotein IIb/IIIa Receptor-directed Monoclonal AntibodiesEzatiostat
go.drugbank.com/drugs/DB05460InvestigationalThis medication is known to target Glutathione S-transferase P. Ezatiostat is a small molecule drug that is an analog inhibitor of glutathione S-transferase P1-1. … It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common, toxic effect of many standard chemotherapeutic drugs.